Samjin studying anti-cancer drug development, SJ-8002.

Published: 2004-08-25 06:56:00

Updated: 2004-08-25 06:56:00

Samjin announced that SJ-8002, an anti-cancer drug of piperazine derivative, was successfully developed having an anti-cancer mode of actions by blocking the microtubule generation, angiogenesis and inducement of tumor cell's apoptosis, which was published in the Aug. edition of International Jou...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK